IL6R and metabolic dysfunction-associated steatotic liver disease: A target-based Mendelian randomization was used to investigate the efficacy of interleukin-6 receptor (IL-6R) blockage, which has been licensed for inflammation-associated disorders, in the treatment of non-alcoholic fatty liver disease.